Orthocell has appointed medical device distributor MontsMed as its exclusive in-country distributor for Remplir in the key Asian market of Hong Kong.
The appointment strengthens Orthocell’s presence in Asia and positions the Company to deliver first Remplir™ surgical cases and sales in the near term. Hong Kong also provides a strategic gateway to the Guangdong–Hong Kong–Macao Greater Bay Area, opening access to a population of around 100 million people.
This milestone builds on Orthocell’s progress in Singapore, where sales and surgical case momentum continue to grow, and supports the upcoming launch in Thailand in 2026, with distributor selection currently underway.
To support this next phase of growth, Orthocell has appointed Mr Hamish Thrum as Commercial Director, responsible for managing distributor networks and driving Remplir™ commercialisation across Australia and Asia.
Orthocell CEO and MD, Paul Anderson, said:
“We are approaching the commercialisation of Remplir in Asia on a country-by-country basis in a very deliberate and considered manner. The appointment of MontsMed as our exclusive distributor in Hong Kong is a key step in our Asian commercialisation strategy.”